Friday, July 10, 2026

pharma · Atopic Dermatitis · Acne Vulgaris

UAS Pharmaceuticals Pty

Galderma Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Atopic Dermatitis, Acne Vulgaris, Prurigo Nodularis. NovaPharmaNews links 4 clinical program(s), 5 drug profile

Castle Hill, AU HQ
2000 Founded
44 Employees
TGA registrant Type
Company details
Status
Public
HQ
Castle Hill, AU
Founded
2000
Employees
44
Programs
4
Drugs
7
Patents
0
Clinical program

Adapalene 0.3% / BPO 2.5% gel

Phase 3 · small molecule · Acne Vulgaris

Adapalene 0.3% / BPO 2.5% gel for Acne Vulgaris is a Phase 3 program (small_molecule) at Galderma Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

← All Galderma Australia Pty Ltd projects Phase 3 small molecule completed

Internal code RD.03.SPR.110232

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Galderma Australia Pty Ltd
Phase
Phase 3
Modality
small_molecule
Indication
Acne Vulgaris
Status
completed
Trials
1

Clinical trials